Esperion Therapeutics (ESPR) said Friday it entered into privately negotiated exchange and subscription agreements with certain holders of $210.1 million of its outstanding 4.00% convertible senior subordinated notes due 2025 who agreed to a combination of $57.5 million of new 5.75% convertible senior subordinated notes maturing in 2030 and around $153.4 million in cash for their notes.
Once the exchange transactions close, expected on Dec. 17, the company said around $54.9 million of the 2025 convertible notes will remain outstanding.
Esperion shares were down over 13% shortly ahead of Friday's opening bell.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。